Currently available smoothened targeted therapies in patients with basal cell nevus syndrome are associated with substantial tumor recurrence and clinical resistance. Strategies bypassing smoothened and/or identifying additional downstream components of the Hedgehog pathway could provide novel antitumor targets with a better therapeutic index. Sry-related high mobility group box 9 (SOX9) is a Hedgehog/glioma-associated oncogene homolog-regulated transcription factor known to be overexpressed in basal cell carcinomas (BCCs). A sequence motif search for SOX9-responsive elements identified three motifs in the promoter region of mammalian target of rapamycin (mTOR). In murine BCC cells, SOX9 occupies the mTOR promoter and induces its transcriptional activity. Short hairpin RNA (shRNA)-mediated knockdown of SOX9, as well as smoothened inhibition by itraconazole and vismodegib, reduces mTOR expression and the phosphorylation of known downstream mTOR targets. These effects culminate in diminishing the proliferative capacity of BCC cells, demonstrating a direct mechanistic link between the Hedgehog and mTOR pathways capable of driving BCC growth. Furthermore, rapamycin, a pharmacologic mTOR inhibitor, suppressed the growth of UV-induced BCCs in Ptch1 þ/e /SKH-1 mice, a model that closely mimics the accelerated BCC growth pattern of patients with basal cell nevus syndrome. Our data demonstrate that Hedgehog signaling converges on mTOR via SOX9, and highlight the SOX9-mTOR axis as a viable additional target downstream of smoothened that could enhance tumor elimination in patients with BCC.
INTRODUCTION
Aberrant Hedgehog (Hh) signaling drives numerous types of human malignancies, including basal cell carcinoma (BCC) (Athar et al., 2014) . Signaling activation occurs when a secreted ligand (e.g., SHH) binds to the transmembrane receptor patched 1 (PTCH1). Unliganded PTCH1 blocks Hh signaling by repressing the activity of a second transmembrane receptor, smoothened (SMO) (Kar et al., 2012) . The binding of ligand to PTCH1 relieves SMO repression, triggering SMO translocation to the primary cilium, where it activates the glioma-associated oncogene homolog family of transcription factors (GLI1-3). GLI then translocates to the nucleus and promotes the transcription of target genes, involved in cell proliferation, metastasis, survival, and stemness, including PTCH1, GLI1, CCND1 (cyclin D1), and bone morphogenic proteins (Briscoe and Therond, 2013; Robbins et al., 2012) .
Alterations in Hh regulatory components (i.e., loss-offunction mutations in PTCH1, gain-of-function mutations in SMO, missense mutations in GLI1 and GLI3, concurrent copy number changes in SUFU and GLI2) drive Hh signaling that is crucial for BCC growth (Athar et al., 2014; Atwood et al., 2012) . In addition, germline mutations in the PTCH allele are responsible for basal cell nevus syndrome (BCNS)/Gorlin syndrome, an autosomal dominant condition (Gorlin, 1987; Hahn et al., 1996; Johnson et al., 1996) . Patients with BCNS typically develop large numbers of BCCs and are at substantially increased risk for other types of Hh-driven neoplasms, including medulloblastomas and rhabdomyosarcomas. Therapies targeted at components of the Hh pathway, including the SMO inhibitor vismodegib, have shown remarkable therapeutic efficacy in patients with BCNS (Tang et al., 2012) . However, subsequent studies have revealed significant tumor recurrence and acquired resistance, primarily through secondary mutations in SMO (i.e., D473G, D473Y, Q477E, and G497W) that impair drug binding and/or reactivate the Hh pathway (Pricl et al., 2015; Sharpe et al., 2015) . Moreover, the presence of SMO variants with diminished or absent drug binding in untreated BCCs suggests that some tumors may be intrinsically refractory to currently available SMO inhibitors (Atwood et al., 2015) , underscoring the need for alternative treatment strategies bypassing SMO and/or identification of additional targets amenable to therapeutic intervention.
Recent data highlight involvement of multiple tumor driver pathways in BCC pathogenesis and suggest that their cooperative interactions with the Hh pathway may likely modulate the downstream Hh signaling network and provide novel therapeutic targets. In this regard, we have recently demonstrated that v-akt murine thymoma viral oncogene homolog (AKT), a serine/threonine protein kinase belonging to the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway, is required for BCC tumorigenesis, and that it acts downstream of the Hh pathway suggesting a crosstalk between Hh signaling and the phosphatidylinositol 3/AKT/mTOR pathway. In this study, we demonstrate that mTOR is a direct transcriptional target of SOX9, an Sry-like high mobility group box transcription factor that is transcriptionally regulated by GLI (Bien-Willner et al., 2007; Eberl et al., 2012; Vidal et al., 2008) . We further show that depletion of SOX9 attenuates mTOR signaling and the proliferative capacity of murine BCC cells, and that the pharmacologic inhibition of mTOR suppresses UV-induced BCC tumorigenesis in Ptch1 þ/e /SKH-1 mice, a model that closely mimics the spontaneous and accelerated growth pattern of BCCs in patients with BCNS.
RESULTS

SOX9 is elevated in BCC
We used Ptch1 þ/e /SKH-1 hairless mice to explore the role of SOX9 in BCC growth. Unlike other relevant murine models, which develop BCCs or squamous cell carcinomas (SCCs) but not both, Ptch1 þ/e /SKH-1 mice (hereafter referred to as Ptch1 þ/e ) develop both tumor types in response to chronic UV exposure, allowing us to decipher the molecular determinants underlying the growth of these tumors in the same genetic background (Chaudhary et al., 2015) . We first assessed SOX9 levels in BCCs and SCCs developed in UV-irradiated Ptch1 þ/e mice. SOX9 levels were strongly elevated in BCCs compared with that observed in nontumor-bearing stroma regions (Figure 1a and c). The majority of cells in BCCs showed elevated SOX9 expression, whereas its expression was limited to only a few cells in SCCs (Figure 1a ). Consistent with murine BCCs, SOX9-positive staining was also confined to tumor cells in the human BCC biopsies (Figure 1b and d) and was mostly absent in nontumor-bearing adjacent tissues in both murine and human BCCs, detectable only in patches in the basal cell layers (Figure 1a and b, arrows). The majority of SCCs (23 of a total of 32 human SCCs represented in a tissue microarray) lacked SOX9 staining ( Figure 1e ). The remaining SCCs showed some degree of SOX9 positivity; however, more than one-half of these had staining in less than 10% of the tumor areas-with the exception of a few cases of invasive and recurrent SCCs (3/4), which showed intense staining comparable to that observed in BCCs (Figure 1e ). Although the relevance of SOX9 to SCC growth requires further validation, our data indicate that SOX9 is predominantly augmented in BCCs.
SOX9 knockdown suppresses the proliferative capacity of murine BCC cells ASZ001 cells, derived from BCCs induced in UV-irradiated Ptch1 þ/e /C57BL6 mice, provide a relevant in vitro BCC model, as they display a cellular morphology virtually identical to that occurring in human BCCs, express typical BCC markers, and are sensitive to SMO inhibition (Aszterbaum et al., 1998; So et al., 2006) . The remaining wild-type Ptch1 allele is also lost in these cells, thus mimicking the germline mutations that occur in patients with BCNS (So et al., 2006) . We confirmed SOX9 expression in ASZ001 cells and assessed the effects of SOX9 knockdown using three different shRNA constructs (shSOX9-1, -2, -3). All three shSOX9 constructs effectively abolished SOX9 and led to concurrent decreases in the cell proliferation markers proliferating cell nuclear antigen and cyclin D1 that we previously showed to be elevated in BCCs (Chaudhary et al., 2015) (Figure 2a ). We further show that SOX9 knockdown significantly diminished (threefold) 5-ethynyl-2 0 -deoxyuridine incorporation-indicative of cells in the S phase-in ASZ001 cells (Figure 2b and c). These data demonstrate that SOX9 functions to promote the growth of BCC cells.
mTOR is a transcriptional target of SOX9
Our recent study showed that AKT activation is required for the growth of BCCs in Ptch1 þ/e mice . While exploring a mechanistic link between the AKT and Hh pathways, we observed that SOX9 and mTOR protein and mRNA levels were markedly increased in Ptch1-deficient primary keratinocytes isolated from newborn Ptch1 þ/e mice compared with wild-type Ptch1 þ/þ keratinocytes, showing 1.7-fold and 1.8-fold increases in SOX9 and mTOR mRNA levels, respectively (Figure 3a and b). The increased mTOR expression concurrent with SOX9 suggested that mTOR may be regulated by Hh transcriptional factors. We carried out a sequence motif search for the canonical consensus motifs for GLI and SOX9 and found that the consensus GLI-binding sequence present in many direct GLI target genes (Hui and Angers, 2011; Kinzler and Vogelstein, 1990) was not present in the mTOR promoter. Instead, at least three SOX9binding motifs ([A/T][A/T]CAA[A/T]G) (Kadaja et al., 2014) were present in the promoter region of mTOR ( Figure 3c ). Electrophoretic mobility gel shift assays demonstrated the binding capacity of nuclear extracts prepared from ASZ001 cells to the e3039 fragment, which was substantially reduced after the shRNA-mediated knockdown of SOX9 ( Figure 3d ). Chromatin immunoprecipitation verified precipitation of the e3039 and e8283 fragments in ASZ001 cells ( Figure 3e ). The binding capacity of the e14096 fragment was weaker than the other two (data not shown) and thus excluded from further analyses. To determine the functionality of the SOX9 binding sequences in transcriptional regulation of mTOR, we performed a luciferase reporter assay in ASZ001 cells. Modest reporter activities were detected in cells transduced with either vector alone (pGL3-Basic) or the þ1 kb fragment (þ1 kb from the transcription start site (TSS); Figure 3f , þ1). The addition of e1 kb upstream region led to threefold increases in the reporter activity ( Figure 3f , e1/þ1), indicating active mTOR transcription in ASZ001 cells. The addition of the e3039 fragment, cloned upstream (5 0 ) of the e1/þ1 region, further enhanced the reporter activity, showing a 4.1fold increase compared with the vector alone (Figure 3f , e3039). The e8283 fragment also showed substantial increases compared with the vector alone, although this is a modest increase as compared with the e1/þ1 fragment (Figure 3f, e8283) . These results demonstrate that the e3039 region is indeed functional in ASZ001 cells and provide evidence for a mechanistic link between SOX9 and mTOR. AL Kim et al.
The SOX9-mTOR Axis as a Target in BCC Pathogenesis mTOR is known to promote cell proliferation and growth through phosphorylation of numerous substrates, including the eukaryotic initiation factor 4E-binding proteins (4E-BPs) and the ribosomal S6 kinases (S6Ks) 1 and 2. Cyclin D1 is also regulated to a limited degree by mTOR-dependent translation (Saxton and Sabatini, 2017) . We show that mTOR colocalizes with SOX9 in ASZ001 cells (Figure 3g ), and that shRNA-mediated SOX9 knockdown reduced the expression of mTOR (Figure 3g and h) and cyclin D1, as well as the phosphorylation of p-4E-BP1 and p-p70S6K ( Figure 3h , lanes 1 vs. 3) to a level comparable to that seen after treatment with the mTOR inhibitor rapamycin (Figure 3h , lanes 2 vs. 3). SOX9-dependent mTOR regulation was further demonstrated using human embryonic kidney (HEK293) cells and HEK293T, a line derived from HEK293 that expresses a mutant version of the SV40 large T antigen (Fonseca et al., 2011) . mTOR is expressed at low levels in HEK293 cells, whereas it is elevated in HEK293T cells. Similar to our findings in ASZ001 cells, SOX9 knockdown resulted in decreased mTOR levels in HEK293T cells (Figure 3i ). Conversely, SOX9 overexpression in HEK293 cells substantially augmented mTOR expression ( Figure 3j ). Taken together, our data indicate that SOX9 participates in regulating mTOR signaling in ASZ001 cells and that the SOX9-mTOR axis is also operative in HEK293 cells.
Hh signaling converges on the mTOR pathway via SOX9
To determine the relevance of the SOX9-mTOR axis in the context of the Hh pathway, we assessed SOX9 and mTOR signaling in ASZ001 cells treated with the SMO inhibitor itraconazole (ITRA), an FDA-approved azole antifungal drug recently shown to be a potent and specific inhibitor of Hh signaling (Kim et al., 2010) . The treatment of ASZ001 cells with ITRA dose-dependently attenuated SOX9 and mTOR levels and the phosphorylation of p70S6K in ASZ001 cells (Figure 4a ), the levels of which were restored by SOX9 overexpression (Figure 4b ). In addition, both ITRA (1e30 mM) and vismodegib (IC50 of 40 mM in ASZ001 cells) substantially reduced mTOR mRNA levels, whereas the thymidylate synthase inhibitor 5-fluorouracil, which is FDAapproved to treat superficial BCCs, had no significant effect on mTOR mRNA levels (shown for 40 mM) ( Figure 4c ). A concurrent decrease in SOX9 and mTOR levels was also observed in BCCs harvested from UV-irradiated Ptch1 þ/e mice treated with orally administered ITRA (100 mg/kg, twice daily, 24 days) (Figure 4d and e). We further show that mTOR is overexpressed in a substantial fraction of human BCCs (Figure 4f ), and mTOR-positive cells were detectable across all three clinical BCC subtypes (i.e., nodular, morpheaform, and superficial BCCs) (Figure 4g , showing nodular and morpheic BCCs). Taken together, our data indicate that the SOX9-mTOR axis could be a viable alternative therapeutic target downstream of SMO. mTOR inhibitor rapamycin suppresses UV-induced growth of BCCs in Ptch1 D/e mice To directly test the in vivo feasibility of targeting mTOR in BCCs, we assessed the ability of the mTOR inhibitor rapamycin to inhibit UV-induced BCC growth in Ptch1 þ/e mice. Sixty minutes before UV irradiation (180 mJ/cm 2 , twice a week), mice received either rapamycin (40 mg/mouse in 100 ml phosphate buffered saline, intraperitoneally, n ¼ 20), or a vehicle control (n ¼ 20) for 36 weeks. Rapamycin treatment substantially reduced the total BCC tumor burden, resulting in 3-fold and 6.6-fold decreases in tumor number and size, respectively (Figure 5a and b) . At week 36, both the number and size of microscopic BCCs were significantly reduced (4-fold and 3.6-fold, respectively) ( Figure 5c and d) , which correlated with decreases in mTOR as well as its substrates (4EBP, p70S6K) and their phosphorylated counterparts (Figure 5e ) in rapamycin-treated animals compared with vehicle-treated controls. Levels of cyclin D1, proliferating cell nuclear antigen, and Ki-67 were also decreased in BCCs harvested from UV-irradiated/rapamycin-treated Ptch1 þ/e mice (Figure 5f and g) . In addition, the tumoradjacent skin of the rapamycin-treated animals showed increased expression of the apoptotic proteins, Bax, and cleaved caspase-3 and showed a concurrent decrease in antiapoptotic Bcl2 levels (Figure 5h ). Our data demonstrate the preclinical efficacy of rapamycin and confirm the importance of mTOR as a potential alternative target in UVinduced BCC tumorigenesis in Ptch1 þ/e mice.
DISCUSSION
SOX9 belongs to group E of the SOX transcription factor family (SOX8, SOX9, and SOX10), which is defined by a common high mobility group box domain originally identified in SRY, the sex-determining gene on the Y chromosome (Lefebvre et al., 2007) . SOX9 is crucial during fetal development, and germline SOX9 mutations cause skeletal malformations, central nervous system dysfunction, and multiple defects in additional organs. SOX9 also contributes to the maintenance of stem/progenitor cells in the liver, pancreas, and hair follicles (Furuyama et al., 2011; Vidal et al., 2005) . Consequently, dysregulated SOX9 expression has been linked to the initiation and growth of a wide range of tumors: it has been shown to enhance proliferation and migration of prostate cancer cells and the formation of pancreatic ductal adenocarcinomas and is also implicated in metastasis and endocrine resistance in breast cancer (Deng et al., 2015; Jeselsohn et al., 2017) . In murine BCCs, SOX9 was recently shown to be required for tumor initiation in a Wnt/b-catenin-dependent manner (Larsimont et al., 2015) . Moreover, cooperative Hh-EGFR signaling promotes synergistic induction of SOX9 in Hh-driven BCCs (Eberl et al., 2012) . These results suggest that Hh signaling can be modulated at multiple levels, and that downstream mediators of SOX9 likely play an important regulatory role in BCC growth.
In that regard, our study has identified mTOR as a transcriptional target of SOX9. We show that consensus SOX9-binding motifs exist in the mTOR promoter, and that SOX9 occupies these sites and induces mTOR transcriptional activity in ASZ001 cells. Furthermore, attenuated mTOR expression and mTOR-dependent growth signaling in SOX9 knockdown ASZ001 cells validate the importance of the SOX9-mTOR axis in BCC growth. In support of its oncogenic role in BCC, SOX9 deletion was recently shown to prevent SMO-driven BCC formation in K14CreER:SmoM2 mice (Larsimont et al., 2015) . In this study, SOX9 was shown to regulate many cancer-specific genes, including those that promote stemness, extracellular matrix deposition, and cytoskeleton remodeling while repressing epidermal differentiation, adding complexity to the transcriptional network underlying BCC growth. Given the difference between their K14CreER:SmoM2 model that carries an activating SMO mutant and our in vitro and in vivo models that reflect UVinduced BCC carcinogenesis, it would be interesting to determine the status of SOX9 regulatory networks in these models. Interestingly, our analysis of their chromatin immunoprecipitation-seq data revealed the presence of several SOX9 binding regions in the mTOR promoter, and similar to our findings, these regions were located distant from the TSS (Larsimont et al., 2015) . Although further investigation is warranted for clarifying the functional relevance of these regions, a large fraction of SOX9 bound regions in chondrocytes are localized at a considerable distance from the TSS (Ohba et al., 2015) . In fact, direct DNA binding through dimeric SOX9 recognition within evolutionarily conserved enhancer elements extends tens to hundreds of kilobases from the TSS of the target gene (Ohba et al., 2015) . Moreover, SOX9 association with the TSS domain has been shown to engage basal activities in chondrocytes and likely occurs via protein-protein interactions with the basal transcription apparatus (Ohba et al., 2015) . Although this may argue for the substantial reporter activities that we observed with the e1 kb region of the mTOR promoter that lacks apparent SOX9-binding motifs, we cannot completely exclude the possibility that SOX9-independent mechanisms can regulate mTOR. In fact, multiple transcriptional factors (e.g., NRF2, AP-1) and pathways (e.g., WNT, RAS, p53) are known to regulate mTOR (Bendavit et al., 2016; Chiarini et al., 2015; Saxton and Sabatini, 2017) . Their relevance to mTOR signaling and BCC pathogenesis remains to be elucidated.
Up to now, the studies exploring the role of mTOR in BCCs have been largely limited to immunohistochemical assessment. These studies show variable degrees of mTOR or p-mTOR staining in BCCs that ranges from 8% to 18% (Brinkhuizen et al., 2014; Gutierrez-Dalmau et al., 2010; Karayannopoulou et al., 2013) . In contrast, our study demonstrates that mTOR is overexpressed in a substantial fraction of human BCCs (56%, n ¼ 50). This variable immunoreactivity may be due in part to the use of different antibodies and staining protocols, as well as to differential antibody specificities. Nevertheless, the substantial reduction in BCC growth observed in our study in rapamycin-treated Ptch1 þ/e /SKH-1 mice underscores the importance of mTOR signaling in BCC tumorigenesis. In support of our data, partial to complete BCC regression, albeit with a limited sample size (n ¼ 4), was recently reported in patients treated with everolimus, a derivative of rapamycin (1.5e3 mg daily for 12 months or longer) (Eibenschutz et al., 2013) . The combined treatment of sonidegib and the phosphatidylinositol 3/mTOR dual inhibitor, dactolisib, was also shown to suppress the emergence of SMO resistance in a medulloblastoma xenograft model, further supporting the relevance of the phosphatidylinositol 3-mTOR pathway in Hh-dependent tumors (Buonamici et al., 2010) . Aberrant mTOR signaling has also been implicated in SCC development (Balagula et al., 2015) . Although our study, demonstrating the preclinical efficacy of rapamycin against UV-induced SCCs in Ptch1 þ/e /SKH-1 mice, confirms the importance of mTOR signaling in SCC growth, it is of interest that SOX9 was largely absent in both murine and human SCCs, excluding the possibility of SOX9 western blotting. (i) mTOR levels in SOX9 knockdown HEK293T cells, detected by western blotting. Histogram: densitometric scanning of western blots, normalized to actin. (j) mTOR expression in SOX9-overexpressing HEK293 cells, assessed by RT-PCR. Histogram: data represent the mean AE SD of two independent experiments. *P ¼ 0.044, **P ¼ 0.037. 4E-BP1, 4E binding protein 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GLI, gliomaassociated oncogene homolog; HEK, human embryonic kidney; mTOR, mammalian target of rapamycin; PTCH1, patched 1; RT-PCR, reverse transcriptase-PCR; SD, standard deviation; SOX9, Sry-related high mobility group box 9; TSS, transcription start site.
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The SOX9-mTOR Axis as a Target in BCC Pathogenesis regulation of mTOR in SCC. It is also worth pointing out that although SOX9 expression was observed in the majority of BCC cells, not all SOX9-positive BCC cells expressed mTOR at a level detectable by immunohistochemistry, suggesting that the SOX9-mTOR axis may be operable in subpopulations of BCCs. In summary, our study, demonstrating the convergence of Hh signaling on mTOR and the preclinical efficacy of targeting mTOR, could provide additional strategies to enhance the therapeutic ratio associated with SMO inhibitor therapy in patients with BCNS. Further investigation of the SOX9 regulatory network may also reveal as yet undefined molecular processes governing BCC pathogenesis and in turn may reveal additional mechanism-driven targets for the chemoprevention and treatment of this most common type of human malignancy.
MATERIALS AND METHODS
Cells and reagents
ASZ001 cells (a gift from Dr Ervin Epstein) were cultured as previously described (So et al., 2006) . HEK293 and HEK293T cells were cultured in DMEM supplemented with 10% fetal bovine serum. Vismodegib and 5-fluorouracil were purchased from Selleckchem (Houston, TX); ITRA was from Sigma-Aldrich (St. Louis, MO) and SPORANOX 100 mg/10 ml from Janssen Pharmaceuticals (Titusville, NJ). Antibodies against mTOR, p-p70S6K, p70S5K, p-4E-BP1, 4E-BP1, and p-AKT were from Cell Signaling Technology (Danvers, MA); cyclin D1, cleaved caspase-3, Bax, and Bcl-2 from Santa Cruz Biotechnology (Santa Cruz, CA); SOX9 and proliferating cell nuclear antigen from Abcam (Cambridge, MA); and b-actin from Sigma-Aldrich.
Western blot analysis, immunohistochemistry, and immunofluorescence
Experiments were performed as previously described (Kim et al., 2002a (Kim et al., , 2002b 
Tissue microarrays
Human BCC tissue microarrays (SK-803a, US Biomax, Rockville, MD) and human SCC tissue microarrays (IMH-323, Novus Biologicals, Littleton CO)-representing a total of 50 BCCs and 32 SCCs, respectively-were used in the immunohistochemical assessment of mTOR and SOX9. The human SCC tissue arrays included two invasive SCCs and two recurrent SCCs. Tissue sections were treated with antigen unmasking solution (Vector Labs, Burlingame, CA) before incubation with primary antibodies and visualized with 3,3-diaminobenzidine, as previously described Liu et al., 2014) . Positive staining for SOX9 and mTOR was defined as nuclear or cytoplasmic staining of a tumor cell, respectively. Scores were assigned using a 0e3 scale to denote the prevalence of positive cells within tumor areas, where 0 ¼ negative (0%), 1 ¼ low (<10%), 2 ¼ moderate (10%e50%), and 3 ¼ high (>50%). Because SOX9 staining was barely detectable in the majority of SCCs examined in this study, scores >1 were considered positive.
SOX9 knockdown and overexpression
shRNA constructs that target both mouse and human SOX9 (29mer shRNA constructs in lentiviral GFP vector [Locus ID 6662]) and scrambled control shRNA were purchased from OriGene (Rockville, MD). Transduction and generation of stable SOX9 knockdown ASZ001 and HEK293T cell lines were performed using shSOX9-1 (TGCATCCGCGAGGCGGTCAGCCAGGTGCT), shSOX9-2 (GTGCGCGTCAACGGCTCCAGCAAGAACAA), and shSOX9-3 (CAGCGAACGCACATCAAGACGGAGCAGCT), according to the guidelines of the Phoenix Retroviral Expression System (Orbigen, San Diego, CA). Mouse myc-tagged Sox9 construct (OriGene, Rockville, MD) was transiently transfected into HEK293 cells according to the manufacturer's instructions.
5-Ethynyl-2 0 -deoxyuridine incorporation assay
The proliferative capacity of SOX9 knockdown ASZ001 cells was assessed using a Click-iT Plus 5-ethynyl-2 0 -deoxyuridine Alexa Fluor 488 Imaging Kit (Thermo Fisher, Waltham, MA). For labeling, 5-ethynyl-2 0 -deoxyuridine was added directly to the cell culture, to a final concentration of 10 mM; cultures were incubated for 2 hours, at which point cells were fixed, permeabilized, and labeled with Alexa Fluor picolyl azidea, according to the manufacturer's instructions.
Animal study
The Institutional Animal Care and Use Committee of the University of Alabama at Birmingham approved the animal studies. Six-to eight-week-old Ptch1 þ/À mice were divided into three groups of 20 each. Group I animals served as an age-matched vehicle control (negative control). Group II and group III animals were irradiated with UV (180 mJ/cm 2 ; twice/week) for 36 weeks. In addition, 60 minutes before UV irradiation, group II received a vehicle (phosphate buffered saline) and group III received intraperitoneal injections of rapamycin (40 mg/mouse in 100 ml phosphate buffered saline). Rapamycin stock (50 mg/ml) was prepared in Cremophor EL and ethanol. The number and sizes of tumors were recorded weekly using an electronic Vernier Caliper, as previously described (Chaudhary et al., 2015) . After 36 weeks, skin and tumor tissues were harvested and processed for histological and biochemical analysis. The ITRA study protocol was previously described .
Statistical analyses
Statistical analyses were performed using Student's t test (two-tailed): P < 0.05 was considered statistically significant. Additional methods are provided in the Supplementary Materials online.
